Short Interest in Biorestorative Therapies, Inc. (NASDAQ:BRTX) Declines By 78.5%

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant decline in short interest in August. As of August 14th, there was short interest totaling 99,687 shares, a decline of 78.5% from the July 30th total of 463,966 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 298,477 shares, the short-interest ratio is currently 0.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

Several large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new position in Biorestorative Therapies in the third quarter valued at about $152,000. DRW Securities LLC bought a new position in shares of Biorestorative Therapies during the 4th quarter worth $55,000. Finally, Virtu Financial LLC increased its holdings in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares during the last quarter. 69.38% of the stock is owned by hedge funds and other institutional investors.

Biorestorative Therapies Price Performance

Shares of BRTX stock opened at $0.22 on Wednesday. The firm has a 50-day moving average of $0.30 and a 200-day moving average of $0.30. Biorestorative Therapies has a one year low of $0.16 and a one year high of $1.89. The company has a market cap of $5.67 million, a P/E ratio of -0.21 and a beta of 0.79.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.